Agostoni Carlo, Goulet Olivier, Kolacek Sanja, Koletzko Berthold, Moreno Luis, Puntis John, Rigo Jacques, Shamir Raanan, Szajewska Hania, Turck Dominique
San Paolo Hospital, University of Milan, Milan, Italy.
J Pediatr Gastroenterol Nutr. 2007 Mar;44(3):392-7. doi: 10.1097/01.mpg.0000258887.93866.69.
Infant and follow-on (or "follow-up") formulae fermented with lactic acid-producing bacteria during the production process contain no viable bacteria in the final product due to their inactivation by heat or other means. In this article the ESPGHAN Committee on Nutrition reviews published information on their clinical evaluation. In a systematic literature review, 2 randomized clinical trials including 933 infants were identified as meeting our predefined inclusion criteria. Our analysis reveals that only limited published data are available on the effects of fermented infant formulae. There are indications from 2 studies that some fermented infant formulae may reduce the occurrence or severity of infectious diarrhea in infants. It is recommended that the effects of fermented infant formulae on infectious diarrhea and other relevant outcomes should be assessed in further randomized controlled trials according to current scientific standards. The available data do not allow general conclusions to be drawn on the use and effects of fermented formulae for infants.
婴儿配方奶粉和后续配方奶粉（或“跟进”配方奶粉）在生产过程中经产乳酸菌发酵，但最终产品中不含活细菌，因为这些细菌已通过加热或其他方式灭活。在本文中，欧洲儿科胃肠病、肝病和营养学会（ESPGHAN）营养委员会回顾了已发表的关于其临床评估的信息。在一项系统的文献综述中，确定有2项包括933名婴儿的随机临床试验符合我们预先设定的纳入标准。我们的分析表明，关于发酵婴儿配方奶粉效果的已发表数据有限。两项研究表明，一些发酵婴儿配方奶粉可能会降低婴儿感染性腹泻的发生率或严重程度。建议根据当前科学标准，在进一步的随机对照试验中评估发酵婴儿配方奶粉对感染性腹泻和其他相关结局的影响。现有数据无法就发酵配方奶粉对婴儿的使用和效果得出一般性结论。
